Tags

Type your tag names separated by a space and hit enter

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Braz J Med Biol Res 2006; 39(4):421-9BJ

Abstract

A high dose of delta9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of delta9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD), a cannabis constituent which is devoid of the typical effects of the plant. This observation led us to suspect that CBD could have anxiolytic and/or antipsychotic actions. Studies in animal models and in healthy volunteers clearly suggest an anxiolytic-like effect of CBD. The antipsychotic-like properties of CBD have been investigated in animal models using behavioral and neurochemical techniques which suggested that CBD has a pharmacological profile similar to that of atypical antipsychotic drugs. The results of two studies on healthy volunteers using perception of binocular depth inversion and ketamine-induced psychotic symptoms supported the proposal of the antipsychotic-like properties of CBD. In addition, open case reports of schizophrenic patients treated with CBD and a preliminary report of a controlled clinical trial comparing CBD with an atypical antipsychotic drug have confirmed that this cannabinoid can be a safe and well-tolerated alternative treatment for schizophrenia. Future studies of CBD in other psychotic conditions such as bipolar disorder and comparative studies of its antipsychotic effects with those produced by clozapine in schizophrenic patients are clearly indicated.

Authors+Show Affiliations

Departamento de Neurologia, Psiquiatria e Psicologia Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil. awzuardi@fmrp.usp.brNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

16612464

Citation

Zuardi, A W., et al. "Cannabidiol, a Cannabis Sativa Constituent, as an Antipsychotic Drug." Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas, vol. 39, no. 4, 2006, pp. 421-9.
Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res. 2006;39(4):421-9.
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Moreira, F. A., & Guimarães, F. S. (2006). Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas, 39(4), pp. 421-9.
Zuardi AW, et al. Cannabidiol, a Cannabis Sativa Constituent, as an Antipsychotic Drug. Braz J Med Biol Res. 2006;39(4):421-9. PubMed PMID: 16612464.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. AU - Zuardi,A W, AU - Crippa,J A S, AU - Hallak,J E C, AU - Moreira,F A, AU - Guimarães,F S, Y1 - 2006/04/03/ PY - 2006/4/14/pubmed PY - 2007/2/17/medline PY - 2006/4/14/entrez SP - 421 EP - 9 JF - Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas JO - Braz. J. Med. Biol. Res. VL - 39 IS - 4 N2 - A high dose of delta9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of delta9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD), a cannabis constituent which is devoid of the typical effects of the plant. This observation led us to suspect that CBD could have anxiolytic and/or antipsychotic actions. Studies in animal models and in healthy volunteers clearly suggest an anxiolytic-like effect of CBD. The antipsychotic-like properties of CBD have been investigated in animal models using behavioral and neurochemical techniques which suggested that CBD has a pharmacological profile similar to that of atypical antipsychotic drugs. The results of two studies on healthy volunteers using perception of binocular depth inversion and ketamine-induced psychotic symptoms supported the proposal of the antipsychotic-like properties of CBD. In addition, open case reports of schizophrenic patients treated with CBD and a preliminary report of a controlled clinical trial comparing CBD with an atypical antipsychotic drug have confirmed that this cannabinoid can be a safe and well-tolerated alternative treatment for schizophrenia. Future studies of CBD in other psychotic conditions such as bipolar disorder and comparative studies of its antipsychotic effects with those produced by clozapine in schizophrenic patients are clearly indicated. SN - 0100-879X UR - https://www.unboundmedicine.com/medline/citation/16612464/Cannabidiol_a_Cannabis_sativa_constituent_as_an_antipsychotic_drug_ L2 - http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006000400001&lng=en&nrm=iso&tlng=en DB - PRIME DP - Unbound Medicine ER -